Stryker Co. (NYSE:SYK) Stock Position Increased by Appleton Partners Inc. MA

Appleton Partners Inc. MA increased its position in shares of Stryker Co. (NYSE:SYK) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,222 shares of the medical technology company’s stock after acquiring an additional 1,400 shares during the period. Appleton Partners Inc. MA’s holdings in Stryker were worth $10,521,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Dynamic Advisor Solutions LLC increased its holdings in shares of Stryker by 2.3% in the third quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock valued at $1,080,000 after buying an additional 67 shares in the last quarter. Wedmont Private Capital grew its holdings in shares of Stryker by 3.9% in the 3rd quarter. Wedmont Private Capital now owns 3,414 shares of the medical technology company’s stock worth $1,178,000 after acquiring an additional 127 shares during the last quarter. Tobam lifted its holdings in shares of Stryker by 9.7% during the third quarter. Tobam now owns 1,206 shares of the medical technology company’s stock valued at $436,000 after purchasing an additional 107 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in shares of Stryker by 34.4% in the 3rd quarter. Pinnacle Bancorp Inc. now owns 430 shares of the medical technology company’s stock valued at $155,000 after purchasing an additional 110 shares during the period. Finally, Albion Financial Group UT purchased a new position in Stryker in the 3rd quarter worth about $108,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $391.42 on Friday. The firm has a market cap of $149.22 billion, a price-to-earnings ratio of 50.44, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The company’s fifty day moving average is $377.25 and its 200-day moving average is $364.47. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of analysts have commented on SYK shares. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Citigroup raised their price objective on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, Truist Financial upped their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.